Guangdong Hengrui Pharmaceutical Co., Ltd
Works in Cardiovascular · Dermatology · ENT · Genetic & rare · Hematology · Immunology · Musculoskeletal · Neurology · Oncology · Renal & urogenital · Respiratory · Women's health
Guangdong Hengrui Pharmaceutical Co., Ltd is a clinical trial sponsor. It has 31 active clinical trials with 4,160 planned participants, across 12 therapeutic areas. Since 2021 it has completed 26 trials and stopped 1 early.
Trial track record · since 2021
Pipeline · 31 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Guangdong Hengrui Pharmaceutical Co., Ltd
Guangdong Hengrui Pharmaceutical Co., Ltd is lead sponsor of 31 active clinical trials on ClinicalTrials.gov, with 4,160 planned participants, in Cardiovascular, Dermatology, ENT, Genetic & rare and other areas. Since 2021 it has completed 26 trials and stopped 1 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Guangdong Hengrui Pharmaceutical Co., Ltd; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-29.
Approve Suite is not affiliated with Guangdong Hengrui Pharmaceutical Co., Ltd.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.